Asia Regenerative Medicine Secures ￥10 Million in Series Pre-A Funding

(VCBeat) July. 13, 2021 -- Asia Regenerative Medicine recently completed a Series Pre-A round of financing worth tens of millions of yuan. This round was led by Sequoia Capital China Seed Fund. The existing investors also made additional investments.

Founded in 2018, Asia Regenerative Medicine is an R&D company that produces bioartificial organs that can take place of the donor organs based on human stem cell technology and tissue engineering technology. Asia Regenerative Medicine is committed to solving the problem of organ shortage and prolonging human life with high quality. The company has set up 5 cell and biomaterial laboratories in Shenzhen, Guangzhou, Wuhan and Hong Kong, and has a technical and business team of 70 people composed of cellular, biomaterial and clinical experts, which is one of the largest research and development teams of bioartificial organs in Asia.

Zheng Lixin, CEO of Asia Regenerative Medicine, who has worked for McKinsey, Johnson & Johnson, SKGF and GSK, said, "Throughout the development of clinical treatment technologies, from the earliest natural drugs and chemicals to traditional medical devices and more recently bio-pharmaceutics as antibodies, the evolution of medical technologies has gradually extended the average human life expectancy to about 80 years. However, the inevitable process of human aging and unexpected diseases and accidents have led to a large number of organ failure. Patients often suffer a lot during the terminal stage of diabetes, kidney disease and other organ diseases. At present, organ transplantation is the best treatment, but the shortage of organ donors makes it hard to use this kind of cure. The goal of Asia Regenerative Medicine is to use the increasingly mature stem cells and tissue engineering technology to make human biosynthetic organs suitable for human transplantation, for the treatment of end-stage organ diseases and transplantation."

Sequoia Capital China is a VC firm focused on seed-stage, mid-stage, late-stage, and growth investments in the fintech sector.

Formed in September 2005, Sequoia Capital China has an impressive and diverse portfolio comprising about 300 dynamic companies that deliver high returns on investment using differentiated technologies and innovative business models, including Alibaba, VIPshop.com, Sina.com, Didi, JD.com, Ourpalm, Qihoo 360, Jumei, Momo, and so on.